SJS Investment Consulting’s Vaxcyte PCVX Stock Holding History

SJS Investment Consulting’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38K	Buy	+41	New	+$2.23K	﹤0.01%	1701

Other funds holding PCVX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

SJS Investment Consulting's PCVX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Vaxcyte (PCVX) in Q2 2026: 41 shares worth $2.38K. The stake represents ﹤0.01% of the portfolio and ranks #1701 among its holdings.

60 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

SJS Investment Consulting held 41 shares of Vaxcyte worth $2.38K as of Q2 2026.
Vaxcyte was a new SJS Investment Consulting position in Q2 2026.
Vaxcyte made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1701 holding.
60 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.